C2N highlights first use of eMTBR-tau243 in Evoke phase 3 data
C2N Diagnostics has unveiled the application of its eMTBR-tau243 plasma assay in the Evoke and Evoke+ Phase 3 clinical trials, presenting findings at the AD/PD 2026 Conference. This analysis demonstrated that both eMTBR-tau243 and p-tau217 levels are independently associated with cognitive and functional decline in early symptomatic Alzheimer’s disease, with their combined assessment offering complementary insights into disease progression.
This development is significant for the longevity and healthspan fields as it underscores the potential of tau biomarkers in refining patient stratification and tailoring therapeutic strategies in Alzheimer’s disease. The ability to predict which patients may experience accelerated decline could enhance the precision of clinical interventions and improve patient outcomes.
C2N’s ongoing commitment to tau-related research tools, including its PrecivityTauDx program, highlights the growing emphasis on biomarker-driven approaches in neurodegenerative disease research. This could pave the way for more effective, targeted therapies in the future.